Homburger advised ADC Therapeutics SA on the agreement.ADC Therapeutics SA (NYSE: ADCT), a Swiss-based commercial-stage oncology-focused biotechnology company, announced that it had entered into a royalty…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
